Frequency of RAS gene mutation and its cooperative genetic events in Southeast Asian adult acute myeloid leukemia.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractRAS gene as one of the most frequently mutated genes in acute myeloid leukemia (AML) has become an attractive target for molecular therapy. The role of oncogenic RAS and its associated genetic events in AML are not yet defined. We examined the frequency of RAS mutation in 239 Thai de novo adult AML patients using polymerase chain reaction-single-strand conformational polymorphism analysis. Thirty-five RAS mutations were found in 32 cases (13%) predominantly classified as M1/M2 (53%) followed by M4/M5 subtype (38%). Ten cases were positive for N-RAS codon 12, 11 cases for N-RAS codon 61, 13 cases for N-RAS codon 13, and one case for K-RAS codon 13. No mutation was found in K-RAS exon 2 or H-RAS. The most common base substitution was the G to A transition at codon 13. Most M1/M2 cases had mutations at codon 12 or 13, whereas M4/M5 cases preferentially affected codon 61. Half of the patients with RAS mutations had abnormal karyotypes with the majority involving chromosomes 21, 11 and 7. Four patients had core-binding factor leukemia and four additional patients had coexisting FLT3 or AML1 mutation. One patient had RAS, FLT3 and t(8;21) and the other had RAS, AML1 point mutation and del(9q). In conclusion, mutation of RAS gene was not as common in the Thais as in the western population. Several additional genetic abnormalities occurred in RAS-mutated patients. Future molecular-targeting approaches should take into account the multiple genetic events that coexist with RAS mutations in AML patients.
CitationEur. J. Haematol. 2006, 77 (1):51-56 Eur. J. Haematol.
JournalEuropean journal of haematology
DescriptionBiomarkers of individual susceptibility: field studiesBiomarker (including alleles if genetic): N-RAS, K-RAS, H-RASEffect studied (phenotype/pathology):frequency and type of RAS mutationsMethod of analysis: PCR-SSCPStudy design: cross-sectionalStudy size: 239 Thai adult AML patientsImpact on outcome (including dose-response):10/239 N-RAS codon 12, 13/239 N-RAS codon 13, 11 N-RAS codon 61, 1/239 K-RAS codon 13Correlation with other biomarkers: 2 of 239 cases had coexistent FLT3 and RAS mutations. Keywords classification: abnormalities;analysis;Acute Disease;Adult;Asia,Southeastern;biomarkers of exposure & effect: field studies;classification;Codon;Core Binding Factor Alpha 2 Subunit;DNA Mutational Analysis;epidemiology;Epidemiology,Molecular;field studies;fms-Like Tyrosine Kinase 3;Female;genetics;Gene Frequency;Humans;Leukemia,Myeloid;Male;Mutation;Proteins;ras Proteins;Research;therapy;Thailand;Tyrosine;genetic;
- Mutations of AML1 in non-M0 acute myeloid leukemia: six novel mutations and a high incidence of cooperative events in a South-east Asian population.
- Authors: Auewarakul CU, Leecharendkeat A, Thongnoppakhun W, Limwongse C, Tocharoentanaphol C
- Issue date: 2006 May
- High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21.
- Authors: Preudhomme C, Warot-Loze D, Roumier C, Grardel-Duflos N, Garand R, Lai JL, Dastugue N, Macintyre E, Denis C, Bauters F, Kerckaert JP, Cosson A, Fenaux P
- Issue date: 2000 Oct 15
- A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia.
- Authors: Bacher U, Haferlach T, Kern W, Haferlach C, Schnittger S
- Issue date: 2007 Jun
- Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia.
- Authors: Dicker F, Haferlach C, Kern W, Haferlach T, Schnittger S
- Issue date: 2007 Aug 15
- RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
- Authors: Side LE, Curtiss NP, Teel K, Kratz C, Wang PW, Larson RA, Le Beau MM, Shannon KM
- Issue date: 2004 Mar